Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04022850
Other study ID # 2018111085
Secondary ID 2021111024PI21/0
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date May 5, 2022
Est. completion date May 5, 2024

Study information

Verified date February 2024
Source Basque Health Service
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The De-imFAR study is a two phase study that aims to carry out and test a structured, evidence-based and theory informed process involving the main stakeholders (managers, professionals, patients and researches) for the design, deployment, and evaluation of targeted de-implementation strategies for reducing potentially inappropriate prescribing (PIP). Specifically, the targeted low-value practice of the DE-imFAR study is the pharmacological prescription of statins in the primary prevention of cardiovascular disease (CVD) in low-risk patients. In order to prevent CVD, one of the leading causes of morbidity and death worldwide, there is general agreement on the indication of lipid-lowering treatment, mainly with statins, in patients with a cardiovascular risk (CVR) measurement greater than 10% over 10 years or in secondary prevention. Whereas, for primary prevention in patients with low CVR (<10%), preventive activities should be focused on the promotion of healthy lifestyles through optimizing diet, increasing physical activity, and stopping smoking. Aims 1. Phase I: To design and model in a collegiate way among the agents involved (professionals, patients, managers and researchers) de-implementation strategies to favour the reduction and / or abandonment of low-value prescription of lipid-lowering drugs in primary prevention of cardiovascular disease. This strategy will be designed using systematic, comprehensive frameworks based on theory and evidence for the design of implementation strategies - the Theoretical Domains Framework (TDF) and the Behavior Change Wheel (BCW), focused on addressing the main determinants (barriers and facilitators) of clinical practice of primary prevention of CVD and adapted to the specific context of primary care in Osakidetza-Basque Health System 2. Phase II: To evaluate the effectiveness and feasibility of several de-implementation strategies derived from the systematic process of identification of determinants and mapping of adapted intervention strategies with the TDF/BCW frameworks: a strategy based on providing evidence-based information communication technology tools to help and guide decision-making (a non-reflective decision assistance strategy); a decision information strategy based on the dissemination of the evidence concerning CVD primary prevention framed in a corporate campaign encouraging family physicians to move away from PIP (a both reflective and non-reflective decision information strategy) ; and a reflective decision structure strategy encouraging reflection on actual performance based on an audit/feedback system (A reflective decision structure strategy). Hypothesis Professionals exposed to the de-implementation strategies derived from the systematic process of identification of determinants and mapping of adapted intervention strategies with the TDF/BCW frameworks, will be effective in reducing and/or abandoning the prescription of statins in primary prevention of CVD. Among the evaluated de-implementation strategies, those that encourage self-reflection on actual performance will obtain the largest effects as compared to non-reflective strategies. Design Phase I formative research to design and model de-implementation strategies and Phase II effectiveness and feasibility evaluation through a cluster randomized implementation trial with an additional control group. Phase I formative research will include the following actions: Cross-sectional observational study of low value pharmacological prescription in the primary prevention of CVD; Literature review on the determinants of low value pharmacological prescription behaviour and effective intervention strategies; Qualitative study on the determinants of low value pharmacological prescription in primary prevention of CVD; Collegiate mapping of the de-implementation strategies; Selection of de-implementation strategies based in perceived effectiveness and feasibility. During Phase II, the evaluation of several de-implementation strategies produced through the phase I formative evaluation will be conducted. A mixed method evaluation will be used: quantitative for assessing the implementation results at the professional level and qualitative for assessing the feasibility and perceived impact of the de-implementation strategies from the family physicians' (FPs) perspective and the experience and satisfaction of patients concerning the clinical care received.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 348
Est. completion date May 5, 2024
Est. primary completion date May 5, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A and older
Eligibility Eligibility for professionals: - FPs belonging to any of the 13 Integrated Healthcare Organizations of Osakidetza - Non-zero annual incidence rate of PIP of statins at baseline (2021) - A minimum cluster size of n =10 patients Eligibility for patients: - 40- to 74-year-old men and 45- to 74-year-old women - No history of statin use - LDL cholesterol levels between 70 and 189 mg/dL and/or TC between 200 and 289 mg/dL - Without ischemic heart disease/CVD - Estimated CVR REGICOR <7.5% - Attend at least one appointment at the participating FPs' practices during the study period from May 2022 to May 2023, and followed until May 2024

Study Design


Intervention

Behavioral:
A non-reflective decision assistance strategy
A strategy based on providing evidence-based information communication technology tools to help and guide decision-making: pop-up reminders and alerts with associated messages incorporated into the REGICOR CVR calculator in OSABIDE (Osakidetza's EHR system) and within the prescription pathway in PRESBIDE (the electronic drug prescribing component).
A both reflective and non-reflective decision information strategy
This strategy consists of a corporate campaign entitled "Stopping Low-Value Prescribing" run by the organization (Osakidetza- Basque Health Service) that provides FPs with the evidence-based Clinical Practice Guidelines for the primary prevention of CVD in low-risk patients.
A reflective decision structure strategy
The strategy involves the sending of regular audit/feedback reports with practice- and organizational-level performance indicators regarding PIP of statins and healthy lifestyle promotion to prompt reflection about their own care practice, provided along with intention formation and goal-setting-focused messages.

Locations

Country Name City State
Spain Primary Care Research Unit of Bizkaia Bilbao Bizkaia

Sponsors (4)

Lead Sponsor Collaborator
Basque Health Service Carlos III Health Institute, European Union, Health Department of the Basque Government

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary De-implementation strategies effectiveness: incidence of the PIP of statins Change in the incidence of the PIP of statins recorded in the EHR in the target population. from baseline to 12 months and 24 months
Primary De-implementation strategies effectiveness: incidence of the provision of advice regarding healthy lifestyles promotion activities Change in the incidence of the provision of advice regarding healthy lifestyles promotion activities recorded in the EHR in the target population. from baseline to 12 months and 24 months
Secondary Reach of recommendations for CVD primary prevention Absolute number and percentage of patients in the target population who received the recommended CVD primary prevention clinical intervention. 12 months
Secondary De-implementation strategies secondary effectiveness: incidence of CVR (REGICOR) Change in the incidence of CVR (REGICOR) recorded in the EHR in the target population. from baseline to 12 months
Secondary FP's adoption: degree to which the recommended CVD primary prevention clinical intervention is adopted by the FPs Percentage of FPs who reduce PIP of statins and/or increase health promotion activities recorded in the EHR in the target population. 12 months
Secondary Strategies implementation fidelity Process indicators of the delivery of and exposure to the de-implementation strategies (percentage of FPs exposed to the strategies compared) 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05586308 - Incentive-based and Media Literacy Informed Approaches to Improve Vaping Cessation N/A
Recruiting NCT05050266 - Enhancing Mental and Physical Health of Women Veterans N/A
Not yet recruiting NCT06298253 - Behavioral Economics to Implement a Traffic Light Nutrition Ranking System: Study 2 N/A
Active, not recruiting NCT04710901 - uTECH: Machine Learning for HIV Prevention Among Substance Using GBMSM N/A
Not yet recruiting NCT05854212 - Behavioral Economics to Implement Nutrition Ranking in Food Pantries N/A
Recruiting NCT06437444 - Asthma Crisis in Paediatrics: Impact of a Care Pathway in Primary and Hospital Care N/A
Recruiting NCT06192511 - Implementing a Novel Consent Process for Biospecimen Research After Newborn Screening N/A
Enrolling by invitation NCT05344378 - Refining and Implementing Technology-Enhanced Family Navigation to Promote Early Access and Engagement With Mental Health Services for Youth With Autism N/A
Enrolling by invitation NCT05390411 - Seeking Objectivity in Allocation of Advanced Heart Failure (SOCIAL HF) Therapies Trial N/A
Enrolling by invitation NCT05172609 - An Exposure-Based Implementation Strategy to Decrease Clinician Anxiety Around Suicide Prevention N/A
Recruiting NCT05360849 - Implementing PrEP for Women Who Inject Drugs N/A
Not yet recruiting NCT05415891 - The IMPROV Project: Improving Mental Health and Substance Use Treatment Provision (IMPROV) Among People Living With HIV (Human Immunodeficiency Virus) in Atlanta N/A
Enrolling by invitation NCT04171830 - Clinical Surveillance Tool to Screen for Unmet Palliative Needs Among Patients in the Final Year of Life N/A
Completed NCT05374239 - Embedding the Fugl-Meyer Assessment in Occupational Therapists' Routine Practice N/A
Not yet recruiting NCT06375551 - K-ORCA: Testing a Decision Support Tool and Group Process for Selecting Interventions N/A
Completed NCT05240222 - Pre-Implementation Enhancement Strategy To Improve Teachers' Intention to Implement Evidence-Based Practices N/A
Not yet recruiting NCT06215131 - Feasibility of Immersive Virtual Reality Dietician Program in Metabolic-dysfunction Associated Steatotic Liver Disease N/A
Not yet recruiting NCT06184945 - Behavioral Economic & Staffing Strategies in the ICU N/A
Not yet recruiting NCT06075108 - The P-KIDs CARE Health Systems Intervention in Tanzania N/A
Withdrawn NCT04249141 - Determinants of Implementation Success Coordinating Ventilator, Early Ambulation and Rehabilitation Efforts